The race against Intuitive Surgical starts with TransEnterix

A number of companies, including TransEnterix, are set to enter the robotic surgery market in the coming years. The market is projected to reach over $20 billion by 2024, but there's this little company named Intuitive Surgical waiting with history and a massive sales and marketing organization on its side.

Can TransEnterix overtake Intuitive Surgical in the robotic surgery race?

A number of companies, including TransEnterix, are set to enter the robotic surgery market in the coming years. The market is projected to reach over $20 billion by 2024, but there's this little company named Intuitive Surgical waiting with history and a

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

This article shows how hard it will be for Titan to compete with Intuitive. I imagine it will be just as hard for TransEnterix to compete.

All these comparisons need to stop. Go look at Intuitive's earnings from the most recent quarter and you'll realize there isn't a comparison. And there never will.

post

Their chance of success has more to do with Intuitive Surgical than anything else. I just don't see a hospital buying a Senhance over anything Intuitive has to offer. They simply cannot compete.

This article shows how hard it will be for Titan to compete with Intuitive. I imagine it will be just as hard for TransEnterix to compete.

Has Titan Medical missed their opportunity with SPORT?

As a medical device rep, and a once proud owner of Titan Medical stock, I am genuinely disappointed in this company because I believe they have a solid product in SPORT. The question, though, is how much longer will it be considered a solid product?

post

Transenterix will likely live or die based upon whether they get FDA approval for Senhance this fall. They have 210 days from the day their stock dropped below $1.00 per share to get back above the dollar mark before they face delisting. The only catalyst that will make this pop back above a buck is a successful 510k.

Their chance of success has more to do with Intuitive Surgical than anything else. I just don't see a hospital buying a Senhance over anything Intuitive has to offer. They simply cannot compete.

post

It looks like the short term pop has already happened. Don't fool for the Senhance trap! The stock will come back to reality once they get approval. No one will buy it! No one!

JPMorgan owns almost $10 million worth of the stock so they believe in the company.

post

It looks like the short term pop has already happened. Don't fool for the Senhance trap! The stock will come back to reality once they get approval. No one will buy it! No one!

Not true at all ! Marketing and economics will work for TransEnterix.



post

Maybe there will be a short term pop with 510k for Senhance but once the market realizes no one wants to buy one the stock will be back where it is now.

It looks like the short term pop has already happened. Don't fool for the Senhance trap! The stock will come back to reality once they get approval. No one will buy it! No one!

post

Transenterix will likely live or die based upon whether they get FDA approval for Senhance this fall. They have 210 days from the day their stock dropped below $1.00 per share to get back above the dollar mark before they face delisting. The only catalyst that will make this pop back above a buck is a successful 510k.

Maybe there will be a short term pop with 510k for Senhance but once the market realizes no one wants to buy one the stock will be back where it is now.

post

Transenterix will likely live or die based upon whether they get FDA approval for Senhance this fall. They have 210 days from the day their stock dropped below $1.00 per share to get back above the dollar mark before they face delisting. The only catalyst that will make this pop back above a buck is a successful 510k.

post

Hey TheWallStreetFox, technicals don't matter for a penny stock.

post

The funny thing is Senhance isn't even approved in Japan.

which means the surgeons there must really want it.

post

They sold one in Japan last month and they are a huge medical device market. That is a quality sale.

The funny thing is Senhance isn't even approved in Japan.

post

Unfortunately Mohan and his team have a tough job ahead trying to convince surgeons Senhance is new and innovative.

They sold one in Japan last month and they are a huge medical device market. That is a quality sale.

post

Unfortunately Mohan and his team have a tough job ahead trying to convince surgeons Senhance is new and innovative.

post

Don't you TRXC and TITXF pumpers find it odd that with all the consolidation in the medical device industry over the last 3 years, there has been no effort to acquire these two companies?

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.